Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

49
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
49

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Establishment of a prognostic score for distant recurrence in follicular thyroid carcinoma.

Endocrine journal·2026
Same author

Clinical predictors of TRAb decline after total thyroidectomy in patients with Graves' disease.

European thyroid journal·2025
Same author

Active surveillance for small papillary thyroid carcinoma.

Endocrine-related cancer·2025
Same author

The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.

Endocrine journal·2025
Same author

Establishment of novel prognostic groups for papillary thyroid carcinoma using a modified risk classification based on tumor extension in the guidelines of the Japan Association of Endocrine Surgery.

Endocrine journal·2025
Same author

Management of thyroid tumors diagnosed cytologically as follicular neoplasms in a high-volume center: utility of a scoring system using serum thyroglobulin level, tumor size, ultrasound testing, and cytological diagnosis.

Endocrine journal·2024

相关实验视频

Updated: May 6, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

911

在差异化甲状腺癌中评估的预后因素

Yasuhiro Ito, Akira Miyauchi

    Endocrine connections
    |December 16, 2025
    PubMed
    概括

    皮囊性甲状腺癌 (PTC) 和卵泡性甲状腺癌 (FTC) 的预后因素不同. 准确评估这些标志物有助于预测结果,并指导对差异化甲状腺癌的治疗.

    科学领域:

    • 内分泌学 在内分泌学.
    • 在瘤学瘤学.
    • 病理学 病理学 病理学

    背景情况:

    • 差异化甲状腺癌包括乳头甲状腺癌 (PTC) 和卵泡甲状腺癌 (FTC),每种都具有不同的生物学行为和预后因素.
    • 通常通过细胞学来诊断PTC,包括瘤大小,淋巴结转移,以及影响疾病无复发存活率 (DFS) 和因果特定存活率 (CSS) 的甲状腺外/外节侵袭.
    • FTC诊断依赖于术后病理,年龄和瘤大小与预后有关,侵入性 (最小,血管侵入性,广泛) 是一个关键决定因素.

    研究的目的:

    • 为了划分 papillary 和 follicular 甲状腺癌的不同预后因素.
    • 要突出各种临床,病理和分子标记在预测差异化甲状腺癌的结果的重要性.
    • 强调需要在整个患者管理过程中进行全面的预后评估.

    主要方法:

    • 对 PTC 和 FTC 中预后因素的现有文献进行审查和综合.
    • 分析临床指标,如年龄,瘤大小和转移.
    • 评估病理特征,包括瘤入侵,变种类型,Ki-67指数和基因突变 (TERT).

    主要成果:

    • 对于PTC,显著的预后因素包括瘤大小,淋巴结转移,甲状腺外/外节入侵,年龄,攻击性变体,Ki-67指数和TERT促进子突变.
    • 对于FTC,年龄和瘤大小与预后不佳有关,血管侵袭的程度至关重要,囊侵袭不如血管侵袭那么重要.
    关键词:
    分化甲状腺癌分化甲状腺癌.动态的动态的动态.毛囊癌:毛囊癌是一种毛囊癌.皮肤状腺癌 (Papillary Carcinoma) 是一种癌症.预后因素 预后因素静态的 静态的 静态

    更多相关视频

    Spontaneous Murine Model of Anaplastic Thyroid Cancer
    05:39

    Spontaneous Murine Model of Anaplastic Thyroid Cancer

    Published on: February 3, 2023

    2.2K
    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
    06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    2.2K

    相关实验视频

    Last Updated: May 6, 2026

    Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
    03:55

    Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

    Published on: June 9, 2023

    911
    Spontaneous Murine Model of Anaplastic Thyroid Cancer
    05:39

    Spontaneous Murine Model of Anaplastic Thyroid Cancer

    Published on: February 3, 2023

    2.2K
    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
    06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    2.2K
  • 动态标志物 (甲状腺蛋白翻倍率,转移性瘤体积翻倍率) 和免疫学指标 (中性粒细胞与淋巴细胞的比率) 在预后和治疗评估中具有实用性.

    • 结论:

    • 预测标志物评估在PTC和FTC之间存在显著差异,需要量身定制的评估.
    • 对预后标志物进行准确的术前,术后和术后评估对于优化差异化甲状腺癌患者管理和治疗策略至关重要.
    • 先进的标记物,包括动态和免疫学指标,为预测预后和监测治疗反应提供了宝贵的见解.